TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01751867
Drug: Decitabine at 20 mg/m2
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
Study: NCT01988090
Drug: 800 IU Vitamin D Supplement
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose
Study: NCT01988090
Drug: 50,000 IU Vitamin D supplement
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose
Study: NCT00273013
Drug: Singulair
Normalized name: Singulair
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Singulair will be available as over encapsulated 10 mg orange tablets.
Study: NCT00380588
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 milligrams per square meter (mg/m2), intravenous (IV)
Study: NCT00380588
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 milligrams per square meter (mg/m2), intravenous (IV)
Study: NCT00632853
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT00632853
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT00632853
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT00003063
Drug: levamisole hydrochloride
Normalized name: Levamisole Hydrochloride
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01407094
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-200mg/day
Study: NCT01407094
Drug: BupropionXL
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150-450 mg/day
Study: NCT02137967
Drug: 20% Formocresol
DrugBank: Cresol (DB11143)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003378
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003378
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003378
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00168610
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03132584
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~* Alemtuzumab will be administered as follows:~  * IV Day 1~ * IV Day 2~ * Target dose IV on Day 3 and 4
Study: NCT01900093
Drug: Acthar Gel
Normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 units of subcutaneous Acthar Gel therapy daily
Study: NCT01986062
Drug: AR11
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02504229
Drug: Gimeracil and Oteracil Porassium Capsules
Normalized name: bendroflumethiazide and potassium
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT02504229
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02608918
Drug: BMS-955176
Normalized name: BMS-955176
DrugBank: BMS-955176 (DB15193)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02109341
Drug: Paclitaxel bound albumine
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01827384
Drug: Adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth (PO)
Study: NCT01827384
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenous (IV)
Study: NCT01827384
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by mouth (PO)
Study: NCT01827384
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by mouth (PO)
Study: NCT01827384
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by mouth (PO)
Study: NCT01827384
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth (PO)
Study: NCT04199325
Drug: uric-acid-lowering drug
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
Study: NCT01910675
Drug: PCC
Normalized name: PCC
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.
Study: NCT00488787
Drug: intranasal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low dose
Study: NCT00488787
Drug: intranasal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medium dose
Study: NCT00488787
Drug: intranasal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high dose
Study: NCT00804115
Drug: Latanoprost with Pilocarpine vs Timolol or Cosopt
Normalized name: latanoprost / timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
Study: NCT03570112
Drug: SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sofosbuvir 400mg and velpatasvir 100mg once daily for 12 weeks
Study: NCT00114062
Drug: denufosol tetrasodium (INS37217) Intravitreal Injection
DrugBank: Denufosol (DB04983)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03639948
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous solution
Study: NCT03639948
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous solution
Study: NCT03639948
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous solution
Study: NCT03639948
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Injectable product
Study: NCT01811147
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-norepinephrine reuptake inhibitor (SNRI) for 24 months.
Study: NCT00227435
Drug: val-mCyd
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01260103
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Study subjects in a fasting state receive TMZ orally once a day for five consecutive days (days 1 through 5) at a starting dose of 200 mg/m2/day. Treatment cycles are repeated every 28 days following the first daily dose of TMZ from the previous cycle. In the absence of PD or unacceptable toxicity, subjects continue to receive TMZ for a maximum of 13 cycles.
Study: NCT04880928
Drug: Eye injection (Mydrane)
Normalized name: aminophylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Tablet [Mudrane GG]
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mydrane 0.2 mg/ml + 3.1 mg/ml~+ 10 mg/ml solution for injection tropicamide / phenylephrine hydrochloride / lidocaine hydrochloride
Study: NCT04880928
Drug: eye drops (Phenylephrin)
Normalized name: Soothe Lubricant Eye Drops
DrugBank: Tetryzoline (DB06764)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine 10%
Study: NCT04880928
Drug: eye drops (Tropicamid)
Normalized name: Soothe Lubricant Eye Drops
DrugBank: Tetryzoline (DB06764)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tropicamid 0,5%
Study: NCT03849339
Drug: CKD-387
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT00129155
Drug: treosulfan
Normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT04405960
Drug: Alfacalcidol 1 MCG Oral Capsule
Normalized name: alfacalcidol 1 MCG Oral Capsule
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects in the intervention group were given 1 µg oral capsule alphacalcidol once daily Subjects in the control group were given placebo once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
Study: NCT04405960
Drug: Sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects in the control group were given placebo containing simple sugar oral capsule once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
Study: NCT01041248
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg every 2 weeks i.v.
Study: NCT03553186
Drug: Tranexamic Acid 100 MG/ML
Normalized name: tranexamic acid 100 MG/ML
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
Study: NCT01059825
Drug: Placebo to Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
Study: NCT01059825
Drug: Ertugliflozin 1 mg
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, 1 mg, once daily for 84 days
Study: NCT00640926
Drug: Radezolid
Normalized name: Radezolid
DrugBank: Radezolid (DB12339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day, orally for 7-10 days
Study: NCT00640926
Drug: Radezolid
Normalized name: Radezolid
DrugBank: Radezolid (DB12339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg/day orally for 7-10 days
Study: NCT00640926
Drug: Radezolid
Normalized name: Radezolid
DrugBank: Radezolid (DB12339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day orally for 7-10 days
Study: NCT05696548
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be administered at a dose of 24mg as oral dose, one a day
Study: NCT05696548
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks
Study: NCT01954030
Drug: CTO and Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03515044
Drug: 40 mg Rifaximin SSD once daily
Normalized name: lisinopril
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SSD once daily (QD)
Study: NCT01059825
Drug: Ertugliflozin 5 mg
Normalized name: ertugliflozin 5 MG
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
Study: NCT01059825
Drug: Ertugliflozin 25 mg
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, 25 mg, once daily for 84 days
Study: NCT01059825
Drug: Sitagliptin 100 mg
Normalized name: SITagliptin 100 MG
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, 100 mg, once daily for 84 days
Study: NCT01059825
Drug: Placebo to Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, matching placebo to 100 mg, once daily for 84 days
Study: NCT01059825
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
Study: NCT02985554
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
Study: NCT03515044
Drug: 80 mg Rifaximin SSD once daily
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SSD once daily (QD)
Study: NCT03515044
Drug: 80 mg Rifaximin SSD twice daily
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SSD twice daily (BID)
Study: NCT02321839
Drug: Intraviteal Ranibizumab 0.5mg
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraviteal Ranibizumab 0.5mg
Study: NCT03922750
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
Study: NCT00812370
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
Study: NCT03922750
Drug: Insulin glargine U100
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive s.c. injections of insulin glargine OD for 16 weeks
Study: NCT02847598
Drug: BIIB059 (litifilimab)
Normalized name: Immunoglobulin g1, anti-(human blood dendritic cell antigen 2) (human-mus musculus monoclonal biib059 .gamma.1-chain), disulfide with human-mus musculus monoclonal biib059 .kappa.-chain, dimer
DrugBank: Litifilimab (DB18864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT00004059
Drug: 7-hydroxystaurosporine
Normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02050074
Drug: Colesevelam
Normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02050074
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01352689
Drug: Combination Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily
Study: NCT02309879
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
Study: NCT02309879
Drug: Magnesium sulphate infusion
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
Study: NCT00197834
Drug: Depakote
Normalized name: Depakote
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02309879
Drug: Magnesium sulphate and Lidocaine infusion
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
Study: NCT00429273
Drug: Guanfacine
Normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
Study: NCT00429273
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
Study: NCT02801292
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single bolus of Ketamine .25 milligrams per kilogram of weight.
Study: NCT01172912
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01172912
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01138956
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days
Study: NCT01172912
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03213301
Drug: Lurbinectedin
Normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.2 mg/m2 i.v. every 3 weeks
Study: NCT01172912
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01172912
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00956189
Drug: amisulpride
Normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
Study: NCT00836355
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
Study: NCT04238195
Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo
Normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: Subjects receive TBPM-PI-HBr + matching Placebo.
Study: NCT04238195
Drug: Moxifloxacin 400mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment D: Subjects receive 1 400 mg tablet of moxifloxacin administered in an open label manner.
Study: NCT04238195
Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: Subjects receive TBPM-PI-HBr.
Study: NCT00001763
Drug: Interleukin-12
Normalized name: interleukin-12
DrugBank: Edodekin alfa (DB15631)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00668395
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
Study: NCT02404103
Drug: Flunisolide HFA
Normalized name: Flunisolide
DrugBank: Flunisolide (DB00180)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04156555
Drug: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Normalized name: amoxicillin-clavulanate 875 mg-125 mg oral tablet
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amoxicillin-clavulanate 1 g twice a day for total of 6 doses
Study: NCT00328627
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin tablets.
Study: NCT00328627
Drug: Alogliptin placebo
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin placebo-matching tablets.
Study: NCT00328627
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone tablets.
Study: NCT00091195
Drug: romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03210038
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes